Australian Government - Department of Health

Medical Services Advisory Committee (MSAC)

1379 - IncobotulinumtoxinA (XEOMIN), injection of, for blepharospasm, cervical dystonia (spasmodic torticollis) and post-stroke spasticity of the upper limb

The documents on this page may not be accessible, should you require assistance accessing the information please contact the MSAC Secretariat.
Application Number1379
Application NameIncobotulinumtoxinA (XEOMIN), injection of, for blepharospasm, cervical dystonia (spasmodic torticollis) and post-stroke spasticity of the upper limb
Description of Medical ServiceIncobotulinumtoxinA for blepharospasm, cervical dystonia (spasmodic torticollis) and post-stroke spasticity of the upper limb
Description of Medical ConditionBlepharospasm is a chronic progressive disorder, defined as involuntary, sporadic or permanent eyelid closure resulting in significant visual disability.

Cervical dystonia (spasmodic torticollis) covers a spectrum of involuntary movements with abnormal posture of the head and shoulder/neck region.

Post-stroke spasticity of the upper limb imposes a considerable humanistic burden. It is not only painful, but is often associated with functional impairment in personal hygiene and dressing, necessitating the help of a family member or professional caregiver.
Consultation Protocol-
Final Protocol-
Reports-
MSAC Outcomes-

Meetings for this Application

Meeting Type:Date:
PASCNot required.
ESC Not required.
MSAC 3 October 2014

Page currency, Latest update: 09 January, 2014